ஃப்ட் பல்கலைக்கழகம் ஆஃப் புளோரிடா கல்லூரி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃப்ட் பல்கலைக்கழகம் ஆஃப் புளோரிடா கல்லூரி மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃப்ட் பல்கலைக்கழகம் ஆஃப் புளோரிடா கல்லூரி மருந்து Today - Breaking & Trending Today

Observational Study Supports Continuing Oral Anticoagulation During PCI


April 06, 2021
For patients sent for an unplanned PCI, a strategy of maintaining oral anticoagulation is not associated with a higher risk of ischemic complications or bleeding when compared with a strategy of interrupting the direct oral anticoagulant (DOAC) or vitamin K antagonist (VKA) a day or two before the procedure, a new observational analysis confirms.
Published in the April 12, 2021, issue of
JACC: Cardiovascular Interventions, the study, drawing on the large SWEDEHEART registry, supports the current recommendations from the European Society of Cardiology (ESC) for uninterrupted oral anticoagulation (U-OAC) in patients with atrial fibrillation, venous thromboembolism, or a mechanical heart valve undergoing unplanned, nonemergent PCI, investigators say. ....

United States , Dimitrios Venetsanos , Dharam Kumbhani , Piera Capranzano , Sanjit Jolly , Bayer Janssen , Bristol Myers Squibb , Dominick Angiolillo , Phd University Of Catania , Md Ut Southwestern Medical Center , American College Of Cardiology , Md Mcmaster University Hamilton Health Sciences , Boehringer Ingelheim , Phd Karolinska Institute University Hospital , Phd University Of Florida College Medicine , European Society Of Cardiology , Cardiovascular Interventions , European Society , Karolinska University Hospital , North American , American College , Medical Center , Hamilton Health Sciences , Florida College , ஒன்றுபட்டது மாநிலங்களில் , தரம் கும்பனி ,

Experts Update Antithrombotic Advice in AF Patients Undergoing PCI


February 09, 2021
Two additional randomized trials along with other analyses published since 2018 have helped to firm up formal guidance around antithrombotic therapy in patients with atrial fibrillation (AF) who are undergoing PCI.
Published yesterday, the updated North American consensus statement continues to recommend triple therapy with a direct oral anticoagulant (DOAC), a P2Y12 inhibitor, and aspirin during the peri-PCI period, after which the aspirin should be discontinued, according to experts from the United States and Canada.
That’s similar to what the group recommended in the last update published in 2018, but the publication of the AUGUSTUS and ENTRUST-AF PCI trials in the past few years “provides a lot of reassurance on the importance of an early discontinuation of aspirin in these patients,” lead author Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), told TCTMD. ....

United States , France General , Jean Philippe Collet , Dominick Angiolillo , Academic Research Consortium , European Society Of Cardiology , Phd University Of Florida College Medicine , American College Of Cardiology Heart Association , North American , Florida College , American College , American Heart Association , North America , European Society , Evidence Gaps , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஜீன் பிலிப் கோலட் , ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் , ஃப்ட் பல்கலைக்கழகம் ஆஃப் புளோரிடா கல்லூரி மருந்து , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் இதயம் சங்கம் , வடக்கு அமெரிக்கன் , புளோரிடா கல்லூரி , அமெரிக்கன் கல்லூரி , அமெரிக்கன் இதயம் சங்கம் , வடக்கு அமெரிக்கா ,